GlassScriptPhysician profile
Thomas P Dunning
NPI 1558365908
$6,600.93
in general payments reported to CMS, 2019-2025
20 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $271 · 2021: $336 · 2022: $1,212 · 2023: $775 · 2024: $1,786 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,630 · Travel and Lodging: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.41 |
| Travel and Lodging | $169.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,365.00 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $767.01 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $611.08 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $497.49 | 2019-2025 | Cequa |
| Allergan, INC. | $483.27 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $421.83 | 2019-2021 | |
| Coopervision INC. | $346.69 | 2019-2025 | Myday Contact Lens |
| Alcon Vision LLC | $267.10 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Shire North American Group INC | $160.69 | 2019 | |
| Abbvie INC. | $150.29 | 2023-2024 | Lumigan, Alphagan P |
| Johnson & Johnson Vision Care, INC. | $147.06 | 2022 | |
| Optos, INC. | $90.92 | 2019 | |
| Seagen INC. | $88.20 | 2022 | |
| Sight Sciences, INC. | $46.14 | 2024 | Omni Surgical System |
| Harrow Eye, LLC | $44.03 | 2025 | Vevye |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.89 | 2019 | |
| Oyster Point Pharma, INC. | $23.63 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $16.30 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dunning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.